一分钟看懂
这是一项关于乳腺癌的II 期 / III 期研究，登记的药物或干预包括Inavolisib；Placebo；Palbociclib；Fulvestrant，当前状态为研究进行中，已停止招募。登记地点显示中国北京、长春、重庆、福建省等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Inavolisib；Placebo；Palbociclib；Fulvestrant · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- The First Hospital of Jilin University · 长春
- The First Affiliated Hospital, Chongqing Medical University · 重庆
- Fujian Medical University Union Hospital · 福建省
- Sun Yet-sen University Cancer Center · 广州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Fudan University Shanghai Cancer Center · 上海
- Hebei Medical University Fourth Hospital · 石家庄
- Tianjin Cancer Hospital · 天津
- Hubei Cancer Hospital · 武汉
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University · 西安
- Henan Cancer Hospital · 郑州
公开的入选条件
- * Confirmed diagnosis of HR+/HER2- breast cancer
- * Metastatic or locally advanced disease not amenable to curative therapy
- * Progression of disease during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen
- * Receiving LHRH agonist therapy for at least 2 weeks prior to Day 1 of Cycle 1 if pre/peri-menopausal
- * Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)
- * Consent to provide fresh or archival tumor tissue specimen
- * Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1); evaluable "bone-only" disease is not eligible; "bone-only" disease with at least one measurable, soft-tissue component, even if considered disease that is limited
- * Eastern Cooperative Oncology Group Performance Status of 0 or 1
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04191499；登记信息更新于 2026-09-11。